|
[1] KRAWITT EL. Autoimmune hepatitis[J]. N Engl J Med,2006,354(1):54-66.
|
|
[2] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004.
|
|
[3] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.
|
|
[4] DYSON JK,WONG LL,BIGIRUMURAME T,et al. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom[J]. Aliment Pharmacol Ther,2018,48(9):951-960.
|
|
[5] van GERVEN NM,VERWER BJ,WITTE BI,et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission[J]. J Hepatol,2013,58(1):141-147.
|
|
[6] LOHSE AW,MIELI-VERGANI G. Autoimmune hepatitis[J]. J Hepatol,2011,55(1):171-182.
|
|
[7] MACK CL,ADAMS D,ASSIS DN,et al. Diagnosis and management of autoimmune hepatitis in adults and children:2019practice guidance and guidelines from the American Association for the study of liver diseases[J]. Hepatology,2019.[Epub ahead of print]
|
|
[8] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267. e1.
|
|
[9] BINICIER OB,GNAY S. The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis:A retrospective study[J]. Croat Med J,2019,60(4):345-351.
|
|
[10] ZACHOU K,GATSELIS NK,ARVANITI P,et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis[J]. Aliment Pharmacol Ther,2016,43(10):1035-1047.
|
|
[11] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.
|
|
[12] ROBERTS SK,LIM R,STRASSER S,et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy[J]. Clin Gastroenterol Hepatol,2018,16(2):268-277.
|
|
[13] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.
|
|
[14] GIANNAKOPOULOS G,VERBAAN H,FRIIS-LIBY IL,et al.Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine[J]. Dig Liver Dis,2019,51(2):253-257.
|
|
[15] THAN NN,WIEGARD C,WEILER-NORMANN C,et al. Longterm fol ow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy[J]. Scand J Gastroenterol,2016,51(3):329-336.
|
|
[16] AL TAII H,HANOUNEH MA,HANOUNEH I,et al. The use of tacrolimus in refractory autoimmune hepatitis in children and adults:A single center experience[J]. Scand J Gastroenterol,2017,52(2):157-158.
|
|
[17] HBENER S,OO YH,THAN NN,et al. Efficacy of 6-Mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance[J]. Clin Gastroenterol Hepatol,2016,14(3):445-453.
|
|
[18] LEGUC,LEGROS L,KAMMERER-JACQUET S,et al. Safety and efficacy of 6-thioguanine as a second-line treatment for autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):290-291.
|
|
[19] HARIDY J,NICOLL A,SOOD S. Methotrexate therapy for autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):288-289.
|
|
[20] CAMPSEN J,ZIMMERMAN MA,TROTTER JF,et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal[J]. Liver Transpl,2008,14(9):1281-1286.
|
|
[21] FERRI S,LONGHI MS,de MOLO C,et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1autoimmune hepatitis[J]. Hepatology,2010,52(3):999-1007.
|
|
[22] CHEN YY,JEFFERY HC,HUNTER S,et al. Human intrahepatic regulatory T cells are functional,require IL-2 from effector cells for survival,and are susceptible to Fas ligand-mediated apoptosis[J]. Hepatology,2016,64(1):138-150.
|
|
[23] DANIEL V,TROJAN K,OPELZ G. Immunosuppressive drugs affect induction of IFNy+Treg in vitro[J]. Hum Immunol,2016,77(1):146-152.
|
|
[24] LIM TY,MARTINEZ-LLORDELLA M,KODELA E,et al. Lowdose interleukin-2 for refractory autoimmune hepatitis[J]. Hepatology,2018,68(4):1649-1652.
|
|
[25] NISHIKAWA H,ENOMOTO H,IWATA Y,et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-γ-inducible protein-10 in autoimmune hepatitis[J]. Medicine(Baltimore),2016,95(12):e3194.
|
|
[26] CHEN L,LU FB,CHEN DZ,et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis[J]. Mol Immunol,2018,93:38-46.
|
|
[27] WU H,LIAO W,LI Q,et al. Pathogenic role of tissue-resident memory T cells in autoimmune diseases[J]. Autoimmun Rev,2018,17(9):906-911.
|
|
[28] LIAN M,ZHANG J,ZHAO L,et al. Interleukin-35 regulates immune microenvironment of autoimmune hepatitis through inducing the expansion of myeloid-derived suppressor cells[J]. Front Immunol,2019,10:2577.
|
|
[29] WEBB GJ,HIRSCHFIELD GM,KRAWITT EL,et al. Cellular and molecular mechanisms of autoimmune hepatitis[J]. Annu Rev Pathol,2018,13:247-292.
|
|
[30] VALGEIRSSON KB,HREINSSON JP,BJRNSSON ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs[J]. Liver Int,2019,39(12):2341-2349.
|
|
[31] NEURATH M. Current and emerging therapeutic targets for IBD[J]. Nat Rev Gastroenterol Hepatol,2017,14(11):688.
|
|
[32] DIESTELHORST J,JUNGE N,JONIGK D,et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis[J]. Sci Rep,2018,8(1):419.
|
|
[33] AOKI N,KIDO M,IWAMOTO S,et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice[J]. Gastroenterology,2011,140(4):1322-1333. e1-e5.
|
|
[34] LONGHI MS,HUSSAIN MJ,BOGDANOS DP,et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2[J]. Hepatology,2007,46(2):472-484.
|
|
[35] UMESHAPPA CS,SINGHA S,BLANCO J,et al. Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines[J]. Nat Commun,2019,10(1):2150.
|
|
[36] ELLEBRECHT CT,BHOJ VG,NACE A,et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science,2016,353(6295):179-184.
|
|
[37] MUCENIC M,MELLO ES,CANADO EL. Chloroquine for the maintenance of remission of autoimmune hepatitis:Results of a pilot study[J]. Arq Gastroenterol,2005,42(4):249-255.
|
|
[38] RAQUEL BENEDITA TERRABUIO D,AUGUSTO DINIZ M,TEOFILO DE MORAES FALCO L,et al. Chloroquine is effective for maintenance of remission in autoimmune hepatitis:Control ed,double-blind,randomized trial[J]. Hepatol Commun,2019,3(1):116-128.
|
|
[39] KORHONEN R,MOILANEN E. Abatacept,a novel CD80/86-CD28 T cell co-stimulation modulator,in the treatment of rheumatoid arthritis[J]. Basic Clin Pharmacol Toxicol,2009,104(4):276-284.
|
|
[40] LIU LL,FENG ML,WANG LN,et al. A case report of successful treatment with plasma exchange for adult-onset Still’s disease with autoimmune hepatitis[J]. J Clin Apher,2010,25(2):74-76.
|
|
[41] EFE C,PURNAK T,OZASLAN E. The diagnosis of autoimmune hepatitis in patients with adult-onset Still’s disease[J]. J Clin Apher,2010,25(4):235; author reply 236.
|
|
[42] LIN R,ZHOU L,ZHANG J,et al. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.
|
|
[43] WEI Y,LI Y,YAN L,et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut,2020,69(3):569-577.
|
|
[44] KESAR V,ODIN JA. Toll-like receptors and liver disease[J].Liver Int,2014,34(2):184-196.
|
|
[45] CZAJA AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis[J]. World J Gastroenterol,2016,22(42):9257-9278.
|
|
[46] WILCK N,MATUS MG,KEARNEY SM,et al. Salt-responsive gut commensal modulates TH17 axis and disease[J].Nature,2017,551(7682):585-589.
|
|
[47] HU ED,CHEN DZ,WU JL,et al. High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier[J]. Cell Immunol,2018,328:24-32.
|
|
[48] EFE C,KAV T,AYDIN C,et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis[J].Dig Dis Sci,2014,59(12):3035-3042.
|
|
[49] BAJAJ JS,ELLWOOD M,AINGER T,et al. Mindfulnessbased stress reduction therapy improves patient and caregiver-reported outcomes in cirrhosis[J]. Clin Transl Gastroenterol,2017,8(7):e108.
|
|
[50] PAIDAS MJ,ANNUNZIATO J,ROMANO M,et al. Pregnancy and multiple sclerosis(MS):A beneficial association. Possible therapeutic application of embryo-specific pre-implantation factor(PIF*)[J]. Am J Reprod Immunol,2012,68(6):456-464.
|
|
[51] HEGDE VL,NAGARKATTI PS,NAGARKATTI M. Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol[J]. PLo S One,2011,6(4):e18281.
|
DownLoad: